161 related articles for article (PubMed ID: 9257052)
1. The effect of HMG-CoA reductase inhibitors on chronic allograft rejection.
Katznelson S
Contrib Nephrol; 1997; 120():97-104. PubMed ID: 9257052
[No Abstract] [Full Text] [Related]
2. Beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Conraads V
J Am Coll Cardiol; 2003 Jun; 41(11):2104; author reply 2104. PubMed ID: 12798591
[No Abstract] [Full Text] [Related]
3. Pravastatin and low-dose cyclosporine treatment prevent islet allograft rejection in mice.
Arita S; Kasraie A; Une S; Ohtsuka S; Atiya A; Shevlin L; Mullen Y
Transplant Proc; 1998 Mar; 30(2):522. PubMed ID: 9532158
[No Abstract] [Full Text] [Related]
4. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
[TBL] [Abstract][Full Text] [Related]
5. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up.
Stojanovic I; Vrtovec B; Radovancevic B; Radovancevic R; Yazdanbakhsh AP; Thomas CD; Frazier OH
J Heart Lung Transplant; 2005 Sep; 24(9):1235-8. PubMed ID: 16143239
[TBL] [Abstract][Full Text] [Related]
6. [HMG-CoA reductase inhibitor, pravastatin].
Tsujita Y
Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1919-28. PubMed ID: 8210434
[No Abstract] [Full Text] [Related]
7. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.
Mehra MR; Uber PA; Vivekananthan K; Solis S; Scott RL; Park MH; Milani RV; Lavie CJ
J Am Coll Cardiol; 2002 Nov; 40(9):1609-14. PubMed ID: 12427413
[TBL] [Abstract][Full Text] [Related]
8. [Dyslipidemia is a risk for patients with kidney transplants. Do statins protect the kidney?].
MMW Fortschr Med; 2000 May; 142(21):69-70. PubMed ID: 10872303
[No Abstract] [Full Text] [Related]
9. Prolongation of islet allograft survival in mice by combined treatment with pravastatin and low-dose cyclosporine.
Arita S; Kasraie A; Une S; Ohtsuka S; Smith CV; Mullen Y
Cell Transplant; 2001; 10(7):639-44. PubMed ID: 11714199
[TBL] [Abstract][Full Text] [Related]
10. Graft Protective Effect of HMG-CoA Reductase Inhibitor Pravastatin in Murine Cardiac Allograft Transplantation.
Yin E; Hara M; Uchiyama M; Niimi M
Transplant Proc; 2018 Nov; 50(9):2804-2806. PubMed ID: 30401401
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients.
Tuncer M; Süleymanlar G; Ersoy FF; Yakupoğlu G
Transplant Proc; 2000 May; 32(3):622-5. PubMed ID: 10812143
[No Abstract] [Full Text] [Related]
12. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Martínez-Castelao A
Med Clin (Barc); 1995 Nov; 105(18):719. PubMed ID: 8538262
[No Abstract] [Full Text] [Related]
13. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
[TBL] [Abstract][Full Text] [Related]
14. The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
Southworth MR; Mauro VF
Ann Pharmacother; 1997 Apr; 31(4):489-91. PubMed ID: 9101013
[TBL] [Abstract][Full Text] [Related]
15. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.
Katznelson S; Kobashigawa JA
Kidney Int Suppl; 1995 Dec; 52():S112-5. PubMed ID: 8587272
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients.
Kobashigawa JA; Moriguchi JD; Laks H; Wener L; Hage A; Hamilton MA; Cogert G; Marquez A; Vassilakis ME; Patel J; Yeatman L
J Heart Lung Transplant; 2005 Nov; 24(11):1736-40. PubMed ID: 16297773
[TBL] [Abstract][Full Text] [Related]
17. Prevention of chronic heart allograft rejection.
Valantine-von Kaeppler HA
Transplant Proc; 1999; 31(1-2):1288-9. PubMed ID: 10083575
[No Abstract] [Full Text] [Related]
18. Does pravastatin safely and effectively improve lipid profiles in children who have received a kidney transplant?
Silverstein DM
Nat Clin Pract Nephrol; 2006 Jun; 2(6):306-7. PubMed ID: 16932448
[No Abstract] [Full Text] [Related]
19. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
20. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Grekas D; Kassimatis E; Makedou A; Bacharaki D; Bamichas G; Tourkantonis A
Nephron; 2001 Aug; 88(4):329-33. PubMed ID: 11474227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
